



Neurotech secures medical devices specialist VDT Psychologie- & Medizilvertrieb as distribution partner

- VDT to exclusively distribute Mente Autism in Germany and Switzerland

Perth, Australia & Malta – 22 May 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has secured VDT Psychologie- & Medizilvertrieb (“VDT”) as its marketing and distribution partner in Germany and Switzerland.

Founded in 1993 and based in Gottingen, VDT is one of the German-speaking world’s oldest and most experienced providers of professional products for biofeedback, neurofeedback and other products for the health care and medicine market. The company provides equipment, systems and consumables from the world’s leading manufacturers, with a focus on delivering independent, competent advice along with fast and uncomplicated service. Additional information is located on its website: <http://www.vdt-biofeedback.de/index.html>.

Training of the local distributor’s sales teams and medical experts has commenced and is ongoing, with various marketing initiatives underway.

Wolfgang Storf, CEO of Neurotech International said: “This is a high quality new partner for Neurotech as we continue our rollout of Mente Autism into one of the largest markets in Europe. VDT Psychologie- & Medizilvertrieb has an excellent track record and experience in this field and we are confident that they are the right choice for our company’s products. Partnering with an established distributor is key to building relationships with medical professionals and entities working in this field and, in particular, with patients on the autism spectrum.”

Matthias Menisch, General Manager of VDT said: “Partnering with Neurotech is a great opportunity to enhance our portfolio and we see Mente Autism as a device designed to add value to everyday life and advance health and wellbeing for those on the autism spectrum.”

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform,

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420